The House Children and Youth Committee, on which I serve as vice chairman, recently held a public hearing to examine the impact of opioids on infants born dependent on the drugs and children of parents and other caregivers who are addicted. I took the opportunity to ask members of the medical community and prevention advocates about the role of pharmaceutical companies in setting the table for the crisis we are facing today.